AI startup Immunai has announced it’s working to map the entire human immune system with $20 million in seed funding to push the project along.
The company, which has operations in Israel as well as the U.S., already has clinical partnerships with 10 medical centers plus commercial collaborations with various biotech and biopharma companies.
“Drugs that improve immune response to cancer are transformational for some patients, but don’t work in 50% to 70% of other patients,” CEO Noam Solomon tells Crunchbase News. “We are trying to understand what therapies work—when they work—by measuring the immune system at high resolutions. We can then use those insights to improve the design of combination therapies.”
Credit: Google News